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Impaired testicular function, i.e., hypogonadism, can result from a primary testicular disorder (hypergonado-
tropic) or occur secondary to hypothalamic-pituitary dysfunction (hypogonadotropic).
Hypogonadotropic hypogonadism can be congenital or acquired. Congenital hypogonadotropic hypogonad-
ism is divided into anosmic hypogonadotropic hypogonadism (Kallmann syndrome) and congenital normosmic
isolated hypogonadotropic hypogonadism (idiopathic hypogonadotropic hypogonadism). The incidence of
congenital hypogonadotropic hypogonadism is approximately 1-10:100,000 live births, and approximately 2/3
and 1/3 of cases are caused by Kallmann syndrome (KS) and idiopathic hypogonadotropic hypogonadism,
respectively.
Acquired hypogonadotropic hypogonadism can be caused by drugs, infiltrative or infectious pituitary lesions,
hyperprolactinemia, encephalic trauma, pituitary/brain radiation, exhausting exercise, abusive alcohol or illicit
drug intake, and systemic diseases such as hemochromatosis, sarcoidosis and histiocytosis X.
The clinical characteristics of hypogonadotropic hypogonadism are androgen deficiency and a lack/delay/stop
of pubertal sexual maturation. Low blood testosterone levels and low pituitary hormone levels confirm the
hypogonadotropic hypogonadism diagnosis. A prolonged stimulated intravenous GnRH test can be useful. In
Kallmann syndrome, cerebral MRI can show an anomalous morphology or even absence of the olfactory bulb.
Therapy for hypogonadotropic hypogonadism depends on the patient’s desire for future fertility. Hormone
replacement with testosterone is the classic treatment for hypogonadism. Androgen replacement is indicated
for men who already have children or have no desire to induce pregnancy, and testosterone therapy is used to
reverse the symptoms and signs of hypogonadism. Conversely, GnRH or gonadotropin therapies are the best
options for men wishing to have children. Hypogonadotropic hypogonadism is one of the rare conditions in
which specific medical treatment can reverse infertility.
When an unassisted pregnancy is not achieved, assisted reproductive techniques ranging from intrauterine
insemination to in vitro fertilization to the acquisition of viable sperm from the ejaculate or directly from the
testes through testicular sperm extraction or testicular microdissection can also be used, depending on the
woman’s potential for pregnancy and the quality and quantity of the sperm.
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& INTRODUCTION
The hypothalamus, the pituitary, and the testes form an
integrated system that is responsible for the adequate
secretion of male hormones and normal spermatogenesis.
The endocrine components of the male reproductive system
are integrated in a classic endocrine feedback loop. The testes
require stimulation by the pituitary gonadotropins, i.e.,
luteinizing hormone (LH) and follicle-stimulating hormone
(FSH), which are secreted in response to hypothalamic
gonadotropin releasing hormone (GnRH). The effect of LH
and FSH on germ cell development is mediated by the
androgen and FSH receptors that are present on Leydig and
Sertoli cells, respectively. Whereas FSH acts directly on the
germinal epithelium, LH stimulates the secretion of testos-
terone by Leydig cells. Testosterone stimulates sperm
production and virilization, in addition to providing feed-
back to the hypothalamus and pituitary to regulate GnRH
secretion. FSH stimulates Sertoli cells to support spermato-
genesis and secrete inhibin B, which negatively regulates FSH
secretion. The GnRH pulse generator is the main regulator of
puberty, and the production of GnRH starts early in fetal life.
As a result, gonadotropin levels change drastically during
fetal development, childhood, puberty and adulthood. Male
infants exhibit what is called a ‘‘window period’’ during the
first six months of life, during which gonadal function can be
clinically detected in response to gonadotropin stimulation.
After that period, serum gonadotropin levels drop and can
only be detected again with the onset of puberty (1).
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Figure 1 - A schematic representation of the components of the hypothalamic-pituitary-testicular axis and the endocrine regulation of
spermatogenesis. Luteinizing hormone (LH) and follicle-stimulating hormone (FSH) are secreted by the pituitary in response to hypothalamic
gonadotropin releasing hormone (GnRH).Whereas FSH acts directly on the germinal epithelium, LH stimulates the secretion of testosterone from
Leydig cells. Testosterone stimulates sperm production and also feeds back to the hypothalamus and pituitary to regulate GnRH secretion. FSH
stimulates Sertoli cells to support spermatogenesis and secrete inhibin B, which negatively regulates FSH secretion.
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This paper aims to review the causes of hypogonado-
tropic hypogonadism, the implications of this condition
depending on the period in which it occurs and the different
types of treatment available.
& DEFINITIONS AND PREVALENCE
Male hypogonadism is characterized by impaired testi-
cular function, which can affect spermatogenesis and/or
testosterone synthesis. Although it is a common endocrine
disorder, the exact prevalence of this disease is unknown.
Male hypogonadism can result from a primary testicular
disorder or occur secondary to hypothalamic-pituitary
dysfunction.
Hypergonadotropic hypogonadism is also known as
primary hypogonadism and is the most frequent form of
hypogonadism found in adult men. The Massachusetts
Male Aging Study (MMAS) reported a crude incidence rate
of 12.3 cases per 1,000 individuals per year, leading to an
estimated prevalence of 481,000 new cases of late-onset
hypogonadism (LOH) per year in American men 40 to 69
years of age (2).
The symptoms of this disorder can include decreased
libido, impaired erectile function, muscle weakness,
increased adiposity, depressed mood, and decreased vitality.
Primary hypogonadism is characterized by low testosterone
production and elevated levels of follicle-stimulating hor-
mone (FSH) and luteinizing hormone (LH) (3). Klinefelter’s
syndrome is the most common congenital manifestation of
primary hypogonadism and affects approximately one in
every 500 men. The acquired forms of hypergonadotropic
hypogonadism include male aging, which affects approxi-
mately 4.1% of men between the ages of 40-49 years and 9.3%
of men between the ages of 60-70 years, and exposure to
gonadotoxic agents such as those used in chemotherapy and
radiotherapy treatments. The latter agents cause gonadal
failure by adversely impacting Leydig and Sertoli cell
function (4).
In contrast to primary hypogonadism, male hypogonado-
tropic hypogonadism (HH) is a consequence of congenital
or acquired diseases that affect the hypothalamus and/or
the pituitary gland (3). In HH, secretion of gonadotropin
releasing hormone (GnRH) is absent or inadequate. Isolated
lack of production or inadequate biosynthesis of pituitary
gonadotropins may also result in HH (5). The prevalence of
this form of hypogonadism has been estimated to range
from 1:10,000 to 1:86,000 individuals (6).
& ETIOLOGY
HH can be congenital or acquired. Congenital HH is
divided in twomain subdivisions depending on the presence
of an intact sense of smell: anosmic HH (Kallmann
syndrome) and congenital normosmic isolated hypogonado-
tropic hypogonadism (idiopathic HH [IHH]). The incidence
of congenital HH is approximately 1-10:100,000 live births,
with approximately 2/3 and 1/3 of cases arising from
Kallmann syndrome (KS) and idiopathic HH, respectively
(7).
Congenital HH can have a genetic origin. The KAL1 gene
has been linked to KS and is the best-characterized gene
related to GnRH deficiency (6). This gene has been mapped
to X-chromosome region Xp22.32 and consists of 14 exons.
KAL1 encodes the protein anosmin-1, which has a length of
840 amino acids and is an extracellular adhesion protein
that plays a possible role in orchestrating GnRH neuron
adhesion and axonal migration. Most KAL-1 mutations are
nucleotide insertions or deletions that result in frame shift
mutations or a premature stop codon. Mutations in this
gene lead to a GnRH migration and olfactory neuron
disorder (8). The failure of GnRH neurons to migrate from
the olfactory placode to their destination in the hypothala-
mus and olfactory lobe represents the basic embryological
defect of this syndrome. The KAL-1 gene accounts for the X-
linked recessive mode of inheritance of familial KS and 10-
20% of all KS cases. The FGR1, GNRHR, NELF, GPRS54,
PROK-2, PROKR-2, CHD-7 and FGF-8 genes have also been
linked to this syndrome. These genes can act alone or in
combination, and mutations in all of these genes lead to
impaired GnRH production (9). Some genetic diseases, such
as Prader-Willi syndrome, Laurence-Moon-Biedl syndrome,
and Moebius syndrome, are also related to HH (6).
IHH is characterized by low levels of gonadotropins and
sex steroids in the absence of anatomical or functional
abnormalities of the hypothalamic–pituitary–gonadal axis.
The pathogenetic mechanism of IHH involves the failure of
GnRH neurons in the hypothalamus to differentiate or
develop, which results in a lack of GnRH secretion or
apulsatile GnRH secretion.
Acquired hypogonadotropic hypogonadism can be
caused by drugs (e.g., sex steroids and gonadotropin-
releasing hormone analogues), infiltrative or infectious
pituitary lesions, hyperprolactinemia, encephalic trauma,
pituitary/brain radiation, exhausting exercise, and abusive
alcohol or illicit drug intake (3). Systemic diseases such as
hemochromatosis, sarcoidosis and histiocytosis X are also
associated with HH (6). The major causes of HH are listed in
Table 1 (3).
& THE ROLE OF GONADOTROPIN RELEASING
HORMONE (GNRH) IN THE PHYSIOLOGICAL
REGULATION OF THE HYPOTHALAMIC-
PITUITARY-GONADAL AXIS
GnRH is a decapeptide that is synthesized by a loose
network of neurons located in the medial basal hypothala-
mus (MBH) and the arcuate nucleus of the hypothalamus.
Some GnRH neurons are found outside the hypothalamus
in the olfactory lobe, reflecting their common embryological
origin. Developmentally, GnRH neurons originate from the
olfactory placode/vomeronasal organ of the olfactory
system and migrate along the vomeronasal nerves to the
Table 1 - Etiologies of Hypogonadotropic Hypogonadism
(3).
Hyperprolactinemia
Pituitary lesions (tumor, granuloma, abscess)
Cushing syndrome
Drug use (opiates, alcohol abuse)
Anabolic steroids use
Severe or chronic illness
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hypothalamus, where they extend processes to the median
eminence and pituitary gland. GnRH is synthesized as a
precursor hormone that contains 92 amino acids and is then
cleaved to a prohormone with a length of 69 amino acids.
The prohormone is further cleaved in the nerve terminals to
form the active decapeptide. GnRH activation is achieved
when specific receptors (i.e., the KiSS1-derived peptide
receptor, also known as GPR54 or the kisspeptin receptor)
are occupied by kisspeptin protein, which is also produced
in the hypothalamus.
Androgens (testosterone and dihydrotestosterone) and
estrogens exert negative feedback by activating specific
receptors that are located on the kisspeptin-secreting
neurons of the arcuate nucleus. Other substances also
influence GnRH secretion. Noradrenaline and leptin have
stimulatory effects, whereas prolactin, dopamine, serotonin,
gamma-aminobutyric acid (GABA) and interleukin-1 are
inhibitory (10).
GnRH has a pulsatile secretion and a half-life of
approximately 10 minutes, and it is secreted into the
hypothalamic-hypophyseal portal blood system, which
carries it to the pituitary gland (11). Once secreted, GnRH
binds to specific pituitary cell membrane receptors, which
results in the production of diacylglycerol and inositol
triphosphate, intracellular calcium increase (by mobilization
from intracellular stores and extracellular influx) and the
activation of protein kinase C. As a consequence, gonado-
tropins (luteinizing hormone [LH] and follicle-stimulating
hormone [FSH]) are released by exocytosis. The GnRH-
receptor complex undergoes intracellular degradation; thus,
the cell requires some time to replace the receptors, which is
reflected by the 60-90 minute interval between GnRH pulses
(12).
The essential function of GnRH is to stimulate the
secretion of LH and FSH from the anterior pituitary gland
(Figure 1). LH and FSH are glycoproteins consisting of
alpha and beta polypeptide chains (a and b subunits). They
have identical alpha subunits but differ in their beta subunit
which determines receptor-binding specificity. Once synthe-
sized, LH and FSH are stored in granules in the pituitary
gland. GnRH induces exocytosis of the granules and the
release of these hormones into the circulation. A low GnRH
pulse frequency tends to preferentially release FSH,
whereas higher frequencies are associated with preferential
secretion of LH (13). Sialization allows FSH to have a longer
(2 hours) half-life than LH (20 minutes). FSH and LH target
specific membrane receptors whose internalization pro-
duces cAMP and protein kinase A. LH initiates male
pubertal development by binding to LH receptors on
Leydig cells, thereby stimulating the release of testosterone.
Sertoli cells have receptors for FSH and testosterone. It is
therefore believed that both FSH and testosterone support
the initiation of spermatogenesis and that both are necessary
for the maintenance of quantitatively normal spermatogen-
esis. Testosterone or its metabolite dihydrotestosterone
binds to androgen receptors on Sertoli cells and then
modulates gene transcription. Functional Sertoli cell andro-
gen receptors are required for normal spermatogenesis.
Intratesticular testosterone levels are ,50 times higher than
serum testosterone levels; therefore, it has been suggested
that the androgen receptors in the normal testis are fully
saturated (14). FSH, in contrast, binds to FSH receptors on
Sertoli cells and initiates signal transduction events that
ultimately lead to the production of inhibin B, which is a
marker of Sertoli cell activity. Inhibin B and testosterone in
turn regulate pituitary FSH secretion (Figure 1). FSH
receptors are expressed in the regions of the seminiferous
tubules that are involved in the proliferation of spermatogo-
nia. The dual hormonal dependence of normal spermatogen-
esis can be appreciated in males with hypogonadotropic
hypogonadism. Sperm production is restored to approxi-
mately 50% of the normal level with either FSH or hCG (as a
surrogate for LH) alone; only the combination of hCG plus
FSH leads to full quantitative restoration (15).
It has been suggested that testicular function is also
regulated by other factors. For instance, Sertoli cells are
influenced by factors secreted by the germ cells. Estrogen
receptors are found in the efferent ducts, Sertoli cells and
most germ cell types. The testes are a major site of estrogen
production; however, direct evidence for a role of estrogen in
spermatogenesis has not yet been identified. The thyroid




The clinical characteristics of HH are androgen deficiency
and a lack/delay/stop in pubertal sexual maturation.
Moreover, hypogonadotropic hypogonadism is considered
idiopathic (IHH) when there is an isolated GnRH secretion
deficiency in individuals over 18 years of age. Below that age,
HH is more properly defined as pubertal delay (1,5). It is
important to consider that the first endocrinological change
to occur during puberty is an increase in LH, which initially
occurs more in amplitude than in frequency and only at
night; subsequently, both LH and FSH levels increase at night
and during the day until adult levels are reached. It is
difficult to differentiate between HH and delayed puberty, as
low gonadotropin and testosterone levels are found in both
conditions. Therefore, a definitive HH diagnosis must be
confirmed only after the patient is 18 years of age (1,17).
When the symptoms are associated with anosmia or
hyposmia without findings such as harelip and cleft palate,
neuro-sensorial deafness, cerebellar ataxia and renal agene-
sia, a diagnosis of Kallmann syndrome should be confirmed.
The appearance of clinical characteristics depends on
when HH begins. When GnRH deficiency occurs in the late
fetal or early neonatal periods and is caused by a lack of the
first intrinsic GnRH peak, which lasts until six months of
age, the incidence of cryptorchidism and/or micro penis is
high (5). Men presenting with HH that started in the pre-
pubertal phase and was triggered by the intrinsic second
GnRH peak exhibit eunuchoid body proportions, a delay in
the development of secondary sexual characteristics, a high-
pitched voice, pre-pubertal testicles, and delayed bone
maturation. Men with an initially delayed HH condition
present with diminished libido, considerable weight gain,
sexual impotence, hot flashes, and infertility. Infertility is
one of the most frequent complaints among these patients
and has a negative effect on their quality of life (3,6). Table 2
shows the most prevalent symptoms of pre- and post-
pubertal hypogonadism (3).
Laboratory and Imaging
Every hypogonadism diagnosis must start with a con-
firmation of low blood testosterone levels, preferably the
free testosterone level, which is based on the total
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testosterone level, albumin level and SHBG level (sexual
hormone-binding globulin). The free and bioavailable
testosterone level can be calculated from the total testoster-
one and SHBG levels (http://www.issam.ch/freetesto.
htm). These laboratory tests should preferably be performed
before 10 am to account for the circadian rhythm of male
hormones. If testosterone levels are low, a new test must be
performed because of high physiological variations. When
low testosterone levels are found, the gonadotropin (FSH
and LH) levels must be analyzed. A low pituitary hormone
level confirms the HH diagnosis (3,5).
HH is characterized as an isolated secretion disorder.
However, some of these releasing gonadotropin hormone
characteristics make direct laboratory tests impossible, as
GnRH is confined within the pituitary portal system and
exhibits a short half-life of 2 to 4 minutes. Therefore, GnRH
levels are better checked by indirect measures such as the
total or partial absence of LH pulses, the regularization of
pituitary and gonadal function, a response to exogenous
GnRH replacement and hormonal reserve tests, which check
the integrity of the hypothalamic-pituitary system’s control
mechanism.
A prolonged stimulated intravenous GnRH test (100 mcg
followed by 500 mcg) can be useful: in hypothalamic GnRH
deficiency, LH and FSH gradually appear, whereas hypo-
responsiveness occurs in the pituitary cases (5). It is
important to note that the diagnosis can only be concluded
after magnetic resonance imaging (MRI) is used for
pituitary, prolactinoma, and craniopharyngioma tumor
exclusion tests (1,6). In Kallmann syndrome, cerebral MRI
can show anomalous morphology or the absence of the
olfactory bulb, and it therefore plays a pivotal role in
presumptive diagnoses.
& THERAPEUTIC MANAGEMENT
The therapy for HH depends on the patient’s desire for
future fertility. Normal androgen levels and the subsequent
development of secondary sex characteristics (in cases
where the onset of hypogonadism occurred before puberty)
and a eugonadal state can be achieved by androgen
replacement alone. Hormone replacement with testosterone
is the classic treatment for hypogonadism. Androgen
replacement is indicated for men who already have children
or have no desire for children, and testosterone therapy is
used to reverse the symptoms and signs of hypogonadism.
The presence of androgens has been linked to a good sexual
life, with preserved libido and erections. The preservation of
muscular strength and lean body mass are related to
androgens, as is bone hemostasis, which prevents osteo-
porosis. Improvements in humor and well-being are
generally the first clinical signs mentioned by patients
who begin hormone replacement.
Conversely, GnRH or gonadotropin therapies are the best
options for men who wish to have children. In such cases,
the stimulation of sperm production requires treatment with
human chorionic gonadotropin (hCG) alone or combined
with recombinant FSH, urinary FSH or human menopausal
gonadotropins (hMG). In the rare cases of ‘fertile eunuchs’,
who produce sufficient FSH but not LH, treatment with
hCG alone may be sufficient to stimulate sperm production
and achieve normal testosterone levels (18).
Treatment for Infertility in Hypogonadotropic
Hypogonadism
Most hypogonadal young men want to be fertile. Thus, it
is important to remember that the fertility of men with
hypogonadotropic hypogonadism is only reduced and that
fertility may be restored through hormone therapy. Men
who present with hypergonadotropic hypogonadism do not
respond to hormone medication because the disorder is
caused by primary testicular failure (3,4). In contrast, in
secondary hypogonadism, the Sertoli cells are deprived of
the stimulus necessary for spermatogenesis. Nevertheless, it
is important to remember that high intra-testicular testos-
terone levels are necessary for spermatogenesis (4).
The fertility of patients with HH can be restored through
the use of GnRH when cases have a hypothalamic origin or,
more commonly, with the use of gonadotropins. Various
gonadotropins, either urinary or recombinant, are presently
available. The urinary gonadotropin forms are produced
from the urine of menopausal women and include human
menopause gonadotropin (hMG), which contains urinary
FSH and LH. Another commonly used urinary gonadotro-
pin is highly purified urinary FSH (3,4,6).
Table 2 - Signs and symptoms of pre- and pos-pubertal hypogonadism (3).
Pre-pubertal hypogonadism Post-pubertal hypogonadism
Eunuchoidal stature Normal stature
Small testes (usually ,6cm3) Testes volume normal to slightly low (.10cm3); soft
Small penis (,5cm) Penis normal size
Lack of normal scrotal rugae and pigmentation Normal scrotal rugae and pigmentation
Small prostate Normal prostate
Scant facial, axillary and pubic hair Thinning of facial, axillary and pubic hair
High pitched voice Normal voice
Gynecomastia Gynecomastia
Infertility Infertility
Lack of libido Loss of libido
Low bone mineral density Low bone mineral density
Low muscle mass, high percentage of body fat Low muscle mass, high percentage of body fat
Mild anemia Mild anemia
Hot flashes
Lack of male pattern baldness
Decrease sense of well-being
Erectile disfunction
Modified from Darby E, Anawalt BD. Male hypogonadism: an update on diagnosis and treatment. Treat Endocrinol. 2005;4(5):293-309.
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Regardless of the hormone used for treatment, the total
number of sperm usually remains below the normal
threshold. This finding does not eliminate the potential for
these patients to become fathers, and impregnation rates can
reach 50 to 80% with a sperm concentration of 5 million per
mL (4,5). The predictors of treatment success are described
as an increased baseline testicular volume, no history of
cryptorchidism, a history of sexual maturation, and no
previous testosterone replacement therapy (5). Even indivi-
duals with a testicular volume of 3 mL can benefit from
treatment, although these patients may need two years of
hormonal therapy before spermatogenesis is triggered (4,5).
Because a long period is necessary to restore spermato-
genesis, it is advised that every man who aims to become a
father start treatment 6 to 12 months before attempting to
conceive (4,5).
GnRH pump treatment:
A portable infusion pump administers pulses of GnRH
into the subcutaneous tissue of the abdominal wall every
2 hours, with doses ranging from 100 to 400 ng/kg. This
treatment lasts approximately four months and is usually
shorter than gonadotropin therapy. However, GnRH usage
is restricted to specialized tertiary hospitals and has a high
cost, in addition to interfering with the patient’s everyday
life (4,5).
Gonadotropin treatment:
This treatment can be administered in all cases of
secondary hypogonadism and is compulsory in cases with
pituitary lesions or a defective GnRH receptor. The b-chains
of LH and hCG are very similar and exhibit similar
properties, such as affinity for receptors on Leydig cells.
Currently, urinary gonadotropins are highly purified and
can be injected subcutaneously, which avoids the induction
of antibodies against the medication (4,5).
Gonadotropic treatment starts with the administration of
1,000 to 2,500 international units (IU) of isolated hCG twice a
week for 8 to 12 weeks. This initial phase is the induction
phase, which is crucial for allowing testosterone levels to
increase. In certain cases, hCG alone can induce spermato-
genesis. In individuals who do not have sufficient endo-
genous FSH, treatment can continue with the co-
administration of 75 to 150 IU hMG three times per week
for up to 18 months, as the presence of FSH is crucial for
stimulating spermatogenesis. Recombinant FSH can be used
in place of hMG, with patients receiving 150 IU three times
per week for the same period of time. This combined
treatment provides considerable testicular growth in most
patients, in addition to spermatogenesis in up to 90% of
patients (4,5).
These treatments demand rigid discipline and persever-
ance because of their duration. Financial support is also
necessary because the medication utilized is expensive.
Reproductive outcomes after treatment for
infertility in HH
Treatment with gonadotropins has been shown to be
effective in males affected by hypogonadotropic hypogo-
nadism, but the final response to hormonal treatment varies
widely from patient to patient (19,20). Spontaneous concep-
tion can be achieved within 6-9 months after beginning
gonadotropin treatment but can require up to two years
(21). Therefore, if a spontaneous pregnancy does not occur
after 20 months (or eight months after achieving a sperm
concentration of 56106/mL) assisted reproductive technol-
ogies may be considered to achieve pregnancy (22).
Intrauterine insemination (IUI) is a good option for men
who have achieved good spermatogenesis (a sperm con-
centration higher than 56106/mL) with hormone therapy
but failed to impregnate their partner. In these cases,
hysterosalpingography should be performed on the partner
to confirm tubal patency. IUI is a less expensive and more
natural way to conceive.
Intracytoplasmic sperm injection (ICSI) is the treatment of
choice for patients who have completed at least one year of
therapy and exhibit sperm concentrations of ,16106/mL or
patients who have sperm concentrations .56106/mL but
have failed to achieve impregnation after 20 months. In
addition to male infertility, the reproductive potential of the
female partner should also be investigated. It is common to
find concomitant female infertility in these cases (22).
Bakircioglu et al. evaluated 22 ICSI attempts with a
pregnancy rate of 54.5% (22). Zorn et al. reported four
men with HH who underwent 10 ICSI cycles after hormone
treatment. This group achieved a 67% fertilization rate and a
30% pregnancy rate per cycle (23).
Until recently, remaining childless, adoption or sperm
donation were the only options for HH patients with
persistent azoospermia despite long periods of hormone
therapy. For these patients, testicular sperm extraction
(TESE) could be an excellent option to achieve a pregnancy
(19,22). Some authors have published results with TESE in
azoospermic men with HH; for example, Fahmy et al. used
TESE to successfully recover spermatozoa in 11 out of 15
patients (73%) and, more recently, Akarsu et al. found
sufficient spermatozoa for ICSI and cryopreservation for
future cycles in all cases (19,24).
Assisted reproductive techniques (ART) are an important
tool for achieving pregnancy in couples where the male
partner has HH. Even couples who achieve spermatogen-
esis with hormonal therapy may not achieve pregnancy or
may require extended periods to achieve pregnancy. This
situation can cause low compliance, anxiety, and discomfort
in the patients and can increase the financial burden (19).
Evaluation of the female partner’s fertility can save time for
the couple, as can using ART to achieve a pregnancy as soon
as possible.
& EXPERT COMMENTARY
Conventionally, gonadotropin therapy in the form of
human chorionic gonadotropin (hCG) alone or combined
with human menopausal gonadotropin (hMG) or follicle-
stimulating hormone (FSH) is indicated to restore sperma-
togenesis in HH men wishing to father a child. The
glycoprotein hormones FSH, LH, hCG are composed of
two non–covalently linked protein subunits: the alpha and
beta subunits. The alpha subunits of the hormones are
identical, whereas the beta subunits are distinct and confer
the unique biological and immunological properties and
receptor specificity of each of these glycoproteins (25). The
beta subunit of LH contains the same amino acid sequence
as the beta subunit of hCG, but the hCG beta subunit
contains an additional 23 amino acids. The two hormones
differ in the composition of their carbohydrate moieties,
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which affect bioactivity and half-life. The half-life of LH is
20 minutes, whereas the half-life of hCG is 24 hours (26).
The history underpinning the development of gonadotro-
pin therapy spans close to 100 years and provides an example
of how basic research and technological advances have
progressed to clinical application. Originally, gonadotropins
were derived from animal (pregnant mare serum) or human
(post-mortem pituitary gland) sources, but these prepara-
tions were abandoned because of safety concerns. The
modern gonadotropin era started in the 1940s with the
extraction of hCG and hMG from urine. Improvements in
purification methods led to the production of urinary
gonadotropins containing FSH only in the 1980s and 1990s.
Advances in DNA technology in the end of the last century
enabled the development of recombinant gonadotropins.
Recombinant human chorionic gonadotropin (rec-hCG), FSH
(rec-hFSH) and LH (rec-hLH), which have the advantage of
being devoid of other gonadotropin hormones and contami-
nants of human origin, have become available, and the use of
recombinant FSH combined with recombinant LH prepara-
tions in anovulatory women suffering from hypogonado-
tropic hypogonadotropism has shown to be an effective way
to promote follicular development (27). However, data are
limited on the effectiveness of these preparations to treat HH
males.
In a recent study, the clinical efficacy, safety, and
tolerability of recombinant human chorionic gonadotropin
(rec-hCG) in restoring spermatogenesis and androgen status
were assessed in a group of men with hypogonadotropic
hypogonadism seeking fertility (28). Eleven men with adult-
onset HH were treated with a single weekly subcutaneous
(SC) injection of 250 mcg of recombinant hCG for a
minimum of 12 weeks. The patients self-administered the
rec-hCG with a ready-to-inject, prefilled syringe. In this
study, the causes of secondary HH were pituitary tumor,
long-term exogenous steroid use that did not respond to
discontinuation, and cranioencephalic trauma. All of the
patients presented with clinical signs of hypoandrogenism
and were azoospermic. The testis histopathology results
(available for six patients) revealed peritubular fibrosis and
maturation arrest. The mean¡SD baseline (pretreat-
ment) hormone levels were as follows: FSH=0.46¡
0.28 mUI/mL, LH=0.39¡0.32 mUI/mL, and total testos-
terone = 41.3¡26.9 ng/dL. All but one of the patients (with
a history of cryptorchidism) exhibited restored spermato-
genesis after a mean treatment duration of 12 weeks. The
average total motile sperm count was 396106 (range 0.0-
156.96106) at the 12th treatment week. Two unassisted
pregnancies and one assisted (via in vitro fertilization-ICSI)
pregnancy were obtained during the follow-up period of
five months. The mean¡SD testosterone levels were
647.5¡219.0 ng/dL at the completion of treatment.
Marked improvements in virilization, libido and erectile
function were also observed after treatment, and the mean
combined testis volume increased from 24 mL before
treatment to 33 mL after treatment. Headache, gynecomas-
tia, and increased estradiol levels were observed in one man
who did not recover spermatogenesis. All of the patients
reported subcutaneous hCG self-administration with mini-
mal to no local side effects and/or discomfort. In this study,
a single weekly injection of rec-hCG effectively restored
spermatogenesis and androgen production in most adult-
onset HH males. In light of the favorable efficacy, safety,
and tolerability profile of rec-hCG, this treatment may be
considered an alternative to intramuscularly injected,
urinary-derived hCG for HH men seeking fertility and
normal androgenic status.
Because of the cost, gonadotropin treatment for fertility
restoration should be used until pregnancy is achieved.
Ideally, the medication should be continued until the
beginning of the second trimester, after which the risk of
miscarriage is low (5). It is also advisable to offer sperm
cryopreservation to such patients as an option for preser-
ving future fertility.
Classically, the duration of gonadotropin treatment for
restoring spermatogenesis is greater than three months.
Older studies estimated the duration of spermatogenesis
(from the differentiation of pale spermatogonia to the
ejaculation of mature spermatozoa) to be approximately 74
days (29). This concept was recently challenged by Misell et
al. (2006), who showed that the appearance of new sperm
in the semen occurred after a mean duration of 64 days. In
their study, men with normal sperm concentrations
ingested deuterated (heavy) water (2H2O) daily and
provided semen samples every two weeks for up to 90
days. The incorporation of the 2H2O label into sperm DNA
was quantified by gas chromatography/mass spectro-
metry, which allowed the percentage of new cells to be
calculated. The mean overall time to the detection of
labeled sperm in the ejaculate was 64¡8 days (range 42-
76). Biological variability was also observed, which contra-
dicts the current belief that the duration of spermatogenesis
is fixed. All of the subjects exhibited more than 70% new
sperm in the ejaculate by day 90, but plateau labeling was
not attained in the majority of the subjects, which suggests
the rapid washout of old sperm in the epididymal reservoir
(30). These data also suggest that in normal men, the sperm
released from the seminiferous epithelium enter the
epididymis in a coordinated manner, with little mixing of
old and new sperm before subsequent ejaculation. This
information is useful as a counseling tool for doctors who
rely on gonadotropin treatment for HH males, in the sense
that monitoring using semen analysis can be tailored
accordingly.
Assisted reproductive techniques can also be used for
couples who are unable to attain an unassisted pregnancy.
Intrauterine insemination (IUI) and in vitro fertilization
(IVF) techniques are available, depending on the woman’s
potential for pregnancy and the quality and quantity of
sperm. In cases where viable spermatozoa are not obtained
by clinical treatment, they are likely to be obtained directly
from the testes through testicular sperm extraction (TESE)
or testicular microdissection as part of an in-vitro fertiliza-
tion program with intracytoplasmic sperm injection (ICSI).
These techniques should be applied before considering the
use of donor sperm.
Contraception is advisable for cases where pregnancy is
achieved, as spermatogenesis may continue after therapy
stops (5). In up to 10% of cases, the patient exhibits a
sustained sperm response and adequate serum testosterone
levels even after the complete withdrawal of medication
(9). This situation is called hypogonadotropic hypogonad-
ism reversal. The mechanism underlying these cases has
not been completely explained, but there appears to be
neuronal plasticity in GnRH-producing cells. Sex steroid
production is thought to be responsible for the net neuronal
stimulus, which has been linked to the secretion of GnRH
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to generate sustained reversal of hypogonadotropic hypo-
gonadism (9).
& KEY ISSUES
N Male hypogonadotropic hypogonadism (HH) is defined
as the failure of the testes to produce androgens and
sperm and is a consequence of congenital or acquired
diseases that affect the hypothalamus and/or the
pituitary gland.
N The signs and symptoms of HH vary according to age.
N Diagnosis requires the determination of serum follicle-
stimulating hormone levels, luteinizing hormone levels
and testosterone levels. MRI scans of the brain and sella
should be considered.
N Androgen replacement therapy should not be used for
the treatment of hypogonadotropic hypogonadal males
desiring fertility.
N HH represents one of the rare conditions in which
specific medical treatment can reverse infertility.
N The induction and maintenance of both spermatogenesis
and androgen production are achieved by the exogenous
administration of gonadotropins.
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